WASHINGTON — AbbVie CEO Richard Gonzalez is in for a congressional tongue-lashing of outsized proportion. And it couldn’t come at a worse time.
Just two years ago, AbbVie seemed on the verge of serious financial trouble. Now, investors are openly proclaiming the pharma giant as one of their favorite stock picks. AbbVie exceeded its projected earnings last month, even while other pharma giants like Merck fell short. Its stock is trading near a 52-week high.